Saad Z. Usmani, MD, FACP, Levine Cancer Institute
Advertisement
Articles by Saad Z. Usmani, MD, FACP, Levine Cancer Institute
Advertisement
Latest Updated Articles
Updates in Multiple Myeloma in the Frontline SettingPublished: January 29th 2021 | Updated:
Updates in Relapsed/Refractory MyelomaPublished: January 29th 2021 | Updated:
Third and Subsequent Line Options for Multiple MyelomaPublished: January 29th 2021 | Updated:
Rapid Readouts: Update of CARTITUDE-1Published: June 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5